Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).

Guenter Emons; Christian Kurzeder; Barbara Schmalfeldt; Alexander Reuss; Nikolaus de Gregorio; Jacobus Pfisterer; Tjoung-Won Park-Simon; Sven Mahner; Willibald Schroeder; Hans-Joachim Lueck; Martin Leonhard Heubner; Lars Christian Hanker; Falk Thiel; Felix Hilpert

doi:10.1200/jco.2014.32.15_suppl.5565

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5565 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5565-5565 ◽

Cited By ~ 1

Author(s):

Guenter Emons ◽

Christian Kurzeder ◽

Barbara Schmalfeldt ◽

Alexander Reuss ◽

Nikolaus de Gregorio ◽

...

Keyword(s):

Ovarian Cancer ◽

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Multicenter Phase ◽

Platinum Resistant ◽

Recurrent Endometrial Cancer

Download Full-text

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0034-1388557 ◽

2014 ◽

Vol 74 (S 01) ◽

Author(s):

F Hilpert ◽

C Kurzeder ◽

B Schmalfeldt ◽

P Neuser ◽

N de Gregorio ◽

...

Keyword(s):

Ovarian Cancer ◽

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Multicenter Phase ◽

Platinum Resistant ◽

Recurrent Endometrial Cancer

Download Full-text

Faculty Opinions recommendation of Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718128610.793486222 ◽

2013 ◽

Author(s):

David Kushner ◽

Erin Medlin

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

Download Full-text

Faculty Opinions recommendation of Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718128610.793485993 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

Download Full-text

Faculty of 1000 evaluation for Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718128610.793486320 ◽

2013 ◽

Author(s):

Steve Plaxe ◽

Kristy Ward

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Resistant Refractory ◽

Multicenter Phase ◽

Platinum Resistant ◽

Etirinotecan Pegol

Download Full-text

Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)

Gynecologic Oncology ◽

10.1016/j.ygyno.2014.03.576 ◽

2014 ◽

Vol 133 (3) ◽

pp. 427-432 ◽

Cited By ~ 25

Author(s):

Günter Emons ◽

Grigor Gorchev ◽

Jalid Sehouli ◽

Pauline Wimberger ◽

Anne Stähle ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Lhrh Agonist ◽

Efficacy And Safety ◽

Multicenter Phase ◽

Platinum Refractory

Download Full-text

Panitumumab and pegylated liposomal doxorubicin to platinum-resistant epithelial ovarian cancer with KRAS wild-type: An ongoing, nonrandomized, multicenter, phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps254 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS254-TPS254 ◽

Cited By ~ 1

Author(s):

K. D. Steffensen ◽

M. Waldstr∅m ◽

B. Lund ◽

K. Bergfeldt ◽

N. Keldsen ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Wild Type ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5503 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5503-5503 ◽

Cited By ~ 5

Author(s):

Sandro Pignata ◽

Domenica Lorusso ◽

Giovanni Scambia ◽

Daniela Sambataro ◽

Stefano Tamberi ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Weekly Paclitaxel ◽

Multicenter Phase ◽

Platinum Resistant ◽

Trial Testing

Download Full-text

Faculty Opinions recommendation of PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718144304.793486590 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Trial ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Resistant ◽

Randomized Phase Ii

Download Full-text

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-004-0818-x ◽

2004 ◽

Vol 54 (4) ◽

pp. 283-289 ◽

Cited By ~ 5

Author(s):

Robert J. Morgan ◽

Timothy W. Synold ◽

David Gandara ◽

Franco Muggia ◽

Sidney Scudder ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Recurrent Ovarian Cancer ◽

Platinum Resistant

Download Full-text

Multicenter Phase II Trial of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyg075 ◽

2003 ◽

Vol 33 (8) ◽

pp. 371-376 ◽

Cited By ~ 18

Author(s):

K. Sato

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Clinical Study ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Study Group ◽

Multicenter Phase ◽

Clinical Study Group

Download Full-text